{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:21:19Z","timestamp":1774362079597,"version":"3.50.1"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1097\/fpc.0000000000000265","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T01:51:15Z","timestamp":1484704275000},"page":"125-134","source":"Crossref","is-referenced-by-count":6,"title":["Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals"],"prefix":"10.1097","volume":"27","author":[{"given":"Sheng-Ju","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Min","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Ji","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Zhao","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Qing","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210213","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature11132","article-title":"PPAR-\u03b3 is a major driver of the accumulation and phenotype of adipose tissue Treg cells","volume":"486","author":"Cipolletta","year":"2012","journal-title":"Nature"},{"key":"R2-1-20210213","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.2337\/db13-1175","article-title":"How does pioglitazone prevent progression of impaired glucose tolerance to diabetes?","volume":"62","author":"Genuth","year":"2013","journal-title":"Diabetes"},{"key":"R3-1-20210213","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"key":"R4-1-20210213","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"key":"R5-1-20210213","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1093\/brain\/awt143","article-title":"Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy","volume":"136","author":"Morat\u00f3","year":"2013","journal-title":"Brain"},{"key":"R6-1-20210213","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/510026a","article-title":"Alzheimer\u2019s disease: the forgetting gene","volume":"510","author":"Spinney","year":"2014","journal-title":"Nature"},{"key":"R7-1-20210213","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/bs.podrm.2015.11.002","article-title":"Pioglitazone","volume":"41","author":"Al-Majed","year":"2016","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"R8-1-20210213","doi-asserted-by":"crossref","first-page":"9000","DOI":"10.1038\/srep09000","article-title":"Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer\u2019s disease","volume":"5","author":"Chang","year":"2015","journal-title":"Sci Rep"},{"key":"R9-1-20210213","doi-asserted-by":"crossref","first-page":"s234","DOI":"10.1055\/s-2000-8525","article-title":"Clinical pharmacokinetics of pioglitazone","volume":"108","author":"Eckland","year":"2000","journal-title":"Exp Clin Endocr Diab"},{"key":"R10-1-20210213","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1742-7843.2009.00457.x","article-title":"The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro","volume":"105","author":"Muschler","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R11-1-20210213","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"R12-1-20210213","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1742-7843.2006.pto_437.x","article-title":"Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors","volume":"99","author":"Jaakkola","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R13-1-20210213","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(11)61662-0","article-title":"Pioglitazone and bladder cancer","volume":"378","author":"Hillaire-Buys","year":"2011","journal-title":"Lancet"},{"key":"R14-1-20210213","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrurol.2012.252","article-title":"Bladder cancer in 2012: challenging current paradigms","volume":"10","author":"Noon","year":"2013","journal-title":"Nat Rev Urol"},{"key":"R15-1-20210213","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","article-title":"Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid","volume":"11","author":"Dai","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R16-1-20210213","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/dmd.107.018010","article-title":"Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone","volume":"36","author":"Tornio","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R17-1-20210213","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fphar.2013.00147","article-title":"Current clinical evidence on pioglitazone pharmacogenomics","volume":"4","author":"Kawaguchi-Suzuki","year":"2013","journal-title":"Front Pharmacol"},{"key":"R18-1-20210213","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2217\/pgs.09.82","article-title":"Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies","volume":"10","author":"Daily","year":"2009","journal-title":"Pharmacogenomics"},{"key":"R19-1-20210213","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/dmd.110.035899","article-title":"Discovery of a novel allelic variant of CYP2C8, CYP2C8*11, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo","volume":"39","author":"Yeo","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"R20-1-20210213","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1248\/bpb.b12-00657","article-title":"Effect of cytochrome P450 2C8*3 on the population pharmacokinetics of pioglitazone in healthy Caucasian volunteers","volume":"36","author":"Kadam","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"R21-1-20210213","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00228-004-0871-8","article-title":"CYP2C8 polymorphism frequencies among malaria patients in Zanzibar","volume":"61","author":"Cavaco","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"R22-1-20210213","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1124\/dmd.31.6.687","article-title":"Genetic polymorphisms of CYP2C8 in Japanese population","volume":"31","author":"Nakajima","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R23-1-20210213","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40262-013-0031-3","article-title":"Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure","volume":"52","author":"Castellan","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"R24-1-20210213","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mcp.2003.26a","article-title":"Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients","volume":"73","author":"Takahashi","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R25-1-20210213","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1472-8206.2007.00494.x","article-title":"Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population","volume":"21","author":"Hilli","year":"2007","journal-title":"Fundam Clin Pharmacol"},{"key":"R26-1-20210213","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.0306-5251.2001.01460.x","article-title":"Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population","volume":"52","author":"Scordo","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R27-1-20210213","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0006-291X(02)02592-5","article-title":"Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms","volume":"299","author":"Yasar","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"R28-1-20210213","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1126\/science.1209396","article-title":"China\u2019s demographic history and future challenges","volume":"333","author":"Peng","year":"2011","journal-title":"Science"},{"key":"R29-1-20210213","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa0908292","article-title":"Prevalence of diabetes among men and women in China","volume":"362","author":"Yang","year":"2010","journal-title":"N Engl J Med"},{"key":"R30-1-20210213","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2337\/db12-0207","article-title":"Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study","volume":"62","author":"Zhou","year":"2013","journal-title":"Diabetes"},{"key":"R31-1-20210213","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S2213-8587(14)70145-7","article-title":"Causes of type 2 diabetes in China","volume":"2","author":"Ma","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R32-1-20210213","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2337\/db12-0454","article-title":"A genome-wide association study identifies GRK5 and RASGRP1 as type 2 diabetes loci in Chinese Hans","volume":"62","author":"Li","year":"2013","journal-title":"Diabetes"},{"key":"R33-1-20210213","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cca.2007.05.008","article-title":"Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus","volume":"383","author":"Li","year":"2007","journal-title":"Clin Chim Acta"},{"key":"R34-1-20210213","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/jhg.2009.41","article-title":"Frequencies of genotypes and alleles of the functional SNPs in CYP2C19 and CYP2E1 in mainland Chinese Kazakh, Uygur and Han populations","volume":"54","author":"Wang","year":"2009","journal-title":"J Hum Genet"},{"key":"R35-1-20210213","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1177\/0091270009354997","article-title":"Influence of CYP3A5 and MDR1 genetic polymorphisms on urinary 6 beta-hydroxycortisol\/cortisol ratio after grapefruit juice intake in healthy Chinese","volume":"50","author":"Li","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"R36-1-20210213","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/gtmb.2012.0256","article-title":"CYP2C8 polymorphism frequencies among Han, Uighur, Hui, and Mongolian Chinese populations","volume":"17","author":"Wu","year":"2013","journal-title":"Genet Test Mol Biomarkers"},{"key":"R37-1-20210213","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0169-409X(02)00076-5","article-title":"CYP2C9 allelic variants: ethnic distribution and functional significance","volume":"54","author":"Xie","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"R38-1-20210213","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/FPC.0b013e32834f45f9","article-title":"Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients","volume":"22","author":"Zhong","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R39-1-20210213","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2710.2011.01298.x","article-title":"Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations","volume":"37","author":"Yin","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"R40-1-20210213","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1006\/bbrc.1998.9992","article-title":"Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population","volume":"254","author":"Yasar","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"R41-1-20210213","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0731-7085(95)01665-1","article-title":"Simultaneous quantitation of pioglitazone and its metabolites in human serum by liquid chromatography and solid phase extraction","volume":"14","author":"Zhong","year":"1996","journal-title":"J Pharm Biomed Anal"},{"key":"R42-1-20210213","first-page":"272","article-title":"Pharmacokinetics of pioglitazone hydrochloride tablets in healthy human subjects","volume":"23","author":"Zhao","year":"2007","journal-title":"Chinese J Clin Pharmacol"},{"key":"R43-1-20210213","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2165\/00003088-200544120-00002","article-title":"Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance","volume":"44","author":"Kirchheiner","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R44-1-20210213","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2217\/pgs.11.65","article-title":"Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective","volume":"12","author":"Manolopoulos","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R45-1-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clpt.2004.08.009","article-title":"Clinical consequences of cytochrome P450 2C9 polymorphisms","volume":"77","author":"Kirchheiner","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R46-1-20210213","doi-asserted-by":"crossref","first-page":"e0116463","DOI":"10.1371\/journal.pone.0116463","article-title":"Warfarin dosage response related pharmacogenetics in Chinese population","volume":"10","author":"Li","year":"2015","journal-title":"PLoS ONE"},{"key":"R47-1-20210213","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2125.2007.02986.x","article-title":"No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone","volume":"65","author":"Kalliokoski","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R48-1-20210213","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2125.2012.04343.x","article-title":"Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone","volume":"75","author":"Aquilante","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"R49-1-20210213","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/phar.1292","article-title":"Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in Healthy African-American Volunteers","volume":"33","author":"Aquilante","year":"2013","journal-title":"Pharmacotherapy"},{"key":"R50-1-20210213","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clpt.2005.06.006","article-title":"CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects","volume":"78","author":"Yin","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R51-1-20210213","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/14740331003623218","article-title":"Pioglitazone: side effect and safety profile","volume":"9","author":"Shah","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"R52-1-20210213","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/sj.clpt.6100273","article-title":"Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus","volume":"83","author":"Becker","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R53-1-20210213","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jcpt.12267","article-title":"In vitro assessment of 39 CYP2C9 variants found in the Chinese population on the metabolism of the model substrate fluoxetine and a summary of their effects on other substrates","volume":"40","author":"Ji","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"R54-1-20210213","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1248\/bpb.b14-00671","article-title":"Impact of CYP2C9 polymorphism found in the Chinese population on the metabolism of propofol in vitro","volume":"38","author":"Lian","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"R55-1-20210213","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bcpt.12159","article-title":"In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride","volume":"114","author":"Dai","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R56-1-20210213","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/aps.2013.123","article-title":"In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population","volume":"34","author":"Dai","year":"2013","journal-title":"Acta Pharmacol Sin"},{"key":"R57-1-20210213","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00228-005-0093-8","article-title":"Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide","volume":"62","author":"Kajosaari","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"R58-1-20210213","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1742-1241.2006.01242.x","article-title":"Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus","volume":"61","author":"Wang","year":"2007","journal-title":"Int J Clin Pract"},{"key":"R59-1-20210213","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/aps.2012.144","article-title":"PPAR-\u03b32 and PTPRD gene polymorphisms influence type 2 diabetes patients\u2019 response to pioglitazone in China","volume":"34","author":"Pei","year":"2013","journal-title":"Acta Pharmacol Sin"},{"key":"R60-1-20210213","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.metabol.2009.10.030","article-title":"Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus","volume":"59","author":"Hsieh","year":"2010","journal-title":"Metabolism"},{"key":"R61-1-20210213","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1463-1326.2008.00905.x","article-title":"The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetes","volume":"10","author":"Li","year":"2008","journal-title":"Diabetes Obes Metab"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:23:44Z","timestamp":1620951824000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201704000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000265","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}